Gabriele Eismann - MERCK Kommanditgesells Member of the Supervisory Board
| MKGAF Stock | USD 156.00 2.75 1.73% |
Executive
Dr. Gabriele Eismann is Independent Member of the Supervisory Board, Employee Representative of MERCK Kommanditgesellschaft auf Aktien since May 9, 2014. He serves as Senior Operational Product Manager. He qualified 19801985 Studies in Chemistry, University of Leipzig. 1985 Diploma in ChemistryInorganic Analytics, University of Leipzig. 1989 Chemist for Analytics and Spectroscopy, University of Leipzig. 1991 Doctorate, University of Hannover. since 2014.
| Age | 56 |
| Tenure | 10 years |
| Professional Marks | Ph.D |
| Phone | 49 6151 72 0 |
| Web | https://www.merckgroup.com |
MERCK Kommanditgesells Management Efficiency
The company has return on total asset (ROA) of 0.0656 % which means that it generated a profit of $0.0656 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1422 %, meaning that it generated $0.1422 on every $100 dollars invested by stockholders. MERCK Kommanditgesells' management efficiency ratios could be used to measure how well MERCK Kommanditgesells manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Gaozhong Zhu | Eagle Pharmaceuticals | N/A | |
| Zeb Booker | cbdMD Inc | N/A | |
| Michael Jafar | Evolus Inc | 37 | |
| Debra Hussain | Eagle Pharmaceuticals | N/A | |
| Lance Blundell | cbdMD Inc | 53 | |
| Daniel JD | Biofrontera | N/A | |
| Lisa Wilson | Eagle Pharmaceuticals | N/A | |
| Tomoko YamagishiDressler | Evolus Inc | N/A | |
| Rui Avelar | Evolus Inc | 56 | |
| Samantha Widdicombe | Biofrontera | N/A | |
| Jeffrey Plumer | Evolus Inc | N/A | |
| Alycia Torres | Biofrontera | N/A | |
| Shannon Charles | cbdMD Inc | N/A | |
| Steven Krill | Eagle Pharmaceuticals | 56 | |
| David Johnson | cbdMD Inc | 54 | |
| Jon MBA | Biofrontera | N/A | |
| Jessica Novak | Evolus Inc | N/A | |
| Francisco Mangual | cbdMD Inc | 45 | |
| Nareg Sagherian | Evolus Inc | N/A | |
| Brian Johnston | Evolus Inc | N/A | |
| Paul Bruinenberg | Eagle Pharmaceuticals | 53 | |
Management Performance
| Return On Equity | 0.14 | |||
| Return On Asset | 0.0656 |
MERCK Kommanditgesells Leadership Team
Elected by the shareholders, the MERCK Kommanditgesells' board of directors comprises two types of representatives: MERCK Kommanditgesells inside directors who are chosen from within the company, and outside directors, selected externally and held independent of MERCK. The board's role is to monitor MERCK Kommanditgesells' management team and ensure that shareholders' interests are well served. MERCK Kommanditgesells' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, MERCK Kommanditgesells' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Matthias Heinzel, CEO Board | ||
| Juergen Glaser, Member of the Supervisory Board and Employee Representative | ||
| Gerhard Schmitz, Head Accounting | ||
| Stefan Oschmann, Vice Chairman of Executive Board and Deputy Chief Executive | ||
| Constantin Fest, Head of Investor Relations | ||
| Michaela Glenck, Member of the Supervisory Board | ||
| Veit Ulshoefer, Member of the Supervisory Board, Employee Representative | ||
| Simon Thelen, Member of the Supervisory Board | ||
| Bernd Reckmann, CEO of Life Science and Performance Materials and Member of Executive Board | ||
| Gabriele Eismann, Member of the Supervisory Board | ||
| Peter Guenter, CEO Board | ||
| Wolfgang Buechele, Member of the Supervisory Board | ||
| Barbara Weiland, Chief Officer | ||
| Belen MD, Chair CEO | ||
| Anke Schenkel, Head of Group Controlling & Risk Management | ||
| Marcus Kuhnert, Group CFO and Member of Executive Board | ||
| KarlLudwig Kley, Chairman of the Executive Board, General Partner | ||
| Alexander Putz, Member of the Supervisory Board | ||
| Siegfried Karjetta, Member of the Supervisory Board | ||
| Friederike Rotsch, Group Compliance | ||
| Dietmar Oeter, Member of the Supervisory Board | ||
| Anne Lange, Member of the Supervisory Board, Employee Representative | ||
| Sascha Held, Member of the Supervisory Board, Employee Representative | ||
| Dirk Toepfer, Chief Officer | ||
| Theo Siegert, Member of the Supervisory Board | ||
| Gregor Schulz, Member of the Supervisory Board | ||
| Daniel Thelen, Member of the Supervisory Board | ||
| Constantin Birnstiel, Head of Group Communications | ||
| Edeltraud Glaenzer, Member of the Supervisory Board, Employee Representative | ||
| Kai Beckmann, Head of Group HR, General Partner and Member of Executive Board | ||
| Helga RuebsamenSchaeff, Member of the Supervisory Board | ||
| KarlHeinz Scheider, Member of the Supervisory Board, Employee Representative | ||
| Udit Batra, CEO Life Science, Member of the Executive Board | ||
| Renate Koehler, Member of the Supervisory Board | ||
| Michael Fletterich, Member of the Supervisory Board, Employee Representative | ||
| Crocifissa Attardo, Member of the Supervisory Board, Employee Representative | ||
| Albrecht Merck, Member of the Supervisory Board | ||
| Christian Raabe, Member of the Supervisory Board, Employee Representative | ||
| Peter Merck, Member of the Supervisory Board | ||
| Mechthild Auge, Member of the Supervisory Board, Employee Representative | ||
| Belen Garijo, Member of the Executive Board, Head of Pharmaceuticals | ||
| Michael Kleinemeier, Member of the Supervisory Board | ||
| Tobias Thelen, Member of the Supervisory Board | ||
| Walter Galinat, CEO Performance Materials, Member of the Executive Board | ||
| Isabel Paoli, Chief Strategy Officer, Head of Communications | ||
| Helene Roeder, Member of the Supervisory Board |
MERCK Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is MERCK Kommanditgesells a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.14 | |||
| Return On Asset | 0.0656 | |||
| Profit Margin | 0.16 % | |||
| Operating Margin | 0.23 % | |||
| Current Valuation | 92.22 B | |||
| Shares Outstanding | 129.24 M | |||
| Shares Owned By Institutions | 61.36 % | |||
| Price To Earning | 33.46 X | |||
| Price To Book | 2.75 X | |||
| Price To Sales | 3.76 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards MERCK Kommanditgesells in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, MERCK Kommanditgesells' short interest history, or implied volatility extrapolated from MERCK Kommanditgesells options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in MERCK Kommanditgesellschaft auf. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. Note that the MERCK Kommanditgesells information on this page should be used as a complementary analysis to other MERCK Kommanditgesells' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Complementary Tools for MERCK Pink Sheet analysis
When running MERCK Kommanditgesells' price analysis, check to measure MERCK Kommanditgesells' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MERCK Kommanditgesells is operating at the current time. Most of MERCK Kommanditgesells' value examination focuses on studying past and present price action to predict the probability of MERCK Kommanditgesells' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MERCK Kommanditgesells' price. Additionally, you may evaluate how the addition of MERCK Kommanditgesells to your portfolios can decrease your overall portfolio volatility.
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes |